



EQUITY RESEARCH

UPDATED

08/25/2025

Loyal

TEAM

Jan-Erik Asplund
Co-Founder
jan@sacra.com

Marcelo Ballve
Head of Research
marcelo@sacra.com

DISCLAIMERS

This report is for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal trade recommendation to you.

This research report has been prepared solely by Sacra and should not be considered a product of any person or entity that makes such report available, if any.

Information and opinions presented in the sections of the report were obtained or derived from sources Sacra believes are reliable, but Sacra makes no representation as to their accuracy or completeness. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a determination at its original date of publication by Sacra and are subject to change without notice.

Sacra accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to Sacra. Sacra may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect different assumptions, views and analytical methods of the analysts who prepared them and Sacra is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

All rights reserved. All material presented in this report, unless specifically indicated otherwise is under copyright to Sacra. Sacra reserves any and all intellectual property rights in the report. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of Sacra. Any modification, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, or selling any report is strictly prohibited. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Sacra. Any unauthorized duplication, redistribution or disclosure of this report will result in prosecution.



Loyal

Biotech company developing drugs to extend the lifespan and healthspan of dogs

#biotechnology

[Visit Website](#)

Details

HEADQUARTERS

San Francisco, CA

CEO

Celine Halioua



FUNDING

\$150,000,000

2025

Valuation

Loyal has raised over \$150 million in total funding, including a \$22 million Series B-2 round in February 2025 led by Valor Equity Partners. The company previously raised \$45 million in a Series B round in March 2024 led by Bain Capital Ventures.

Investors include Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, and Quiet Capital. These funding rounds have financed clinical trials and regulatory approval processes, with the most recent capital allocated to manufacturing scale-up and commercial launch preparation.

Product

Loyal is developing three FDA-regulated drugs aimed at extending healthy lifespan in dogs by addressing the biological mechanisms of aging prior to disease onset. Instead of managing symptoms after illness occurs, these medications target metabolic and hormonal pathways that drive aging.

LOY-002 is a beef-flavored daily pill for senior dogs that mimics the longevity effects of caloric restriction without requiring reduced food intake. The drug modulates metabolism in dogs aged 10 and older, drawing on studies that have demonstrated significant lifespan extension through calorie reduction. Loyal has enrolled 1,300 dogs across 70 veterinary clinics in what it describes as the largest animal clinical trial conducted to date.

LOY-001 and LOY-003 are designed for large breed dogs, which have significantly shorter lifespans compared to smaller breeds. These treatments reduce IGF-1, a growth hormone that remains elevated in large dogs and is associated with accelerated aging. LOY-001 is administered as an injection every few months, while LOY-003 provides the same mechanism in a daily pill format licensed from Crinetics Pharmaceuticals.

All three drugs are intended to integrate seamlessly into existing veterinary care, with treatments administered during routine checkups or provided through prescription refills, similar to other chronic medications.

Business Model

Loyal operates as a vertically integrated pharmaceutical company that develops prescription drugs distributed through veterinary channels. The company employs a B2B2C model in which veterinarians prescribe medications to dog owners, mirroring the distribution approach used for heartworm preventatives and arthritis treatments.

The business model relies on recurring monthly subscriptions, with dog owners paying less than \$100 per month for daily pills or receiving periodic injections at veterinary clinics. This structure generates predictable revenue streams tied to pet ownership rather than one-time treatments for specific illnesses.

Loyal is establishing in-house manufacturing capabilities, including a tableting facility in Denver, to reduce costs and improve supply chain reliability. By managing production internally instead of outsourcing to contract manufacturers, the company aims to achieve gross margins exceeding 50%.

The regulatory pathway offers competitive advantages through FDA conditional approval. This process enables Loyal to commercialize drugs after demonstrating safety and a reasonable expectation of effectiveness, with full efficacy to be proven over five years of post-market studies. This approach provides a multi-year lead over competitors while generating revenue to support ongoing development.

Competition

Prescription longevity platforms

Rejuvenate Bio is a direct competitor, developing gene therapy approaches for canine aging. Their dual-gene therapy targets mitral valve disease and osteoarthritis through one-time injections, contrasting with Loyal's chronic medication model. Gene therapy, however, presents significant pricing challenges for pet owners and carries higher safety risks compared to small molecule drugs.

Regulatory barriers play a critical role in this segment. Loyal has secured the first two FDA determinations of reasonable expectation of effectiveness for lifespan extension drugs. Competitors face an additional 2-4 years of clinical trials to achieve similar regulatory milestones, creating a measurable lead for Loyal.

Nutraceutical and supplement players

An expanding category of over-the-counter longevity supplements appeals to pet owners seeking aging interventions without prescription requirements. Companies such as Leap Years and Animal Bioscience market nutraceuticals with anti-aging claims, while established pet supplement brands are introducing longevity-focused products.

These competitors can enter the market more quickly without FDA approval but lack the clinical validation and efficacy data required for prescription drugs. This regulatory distinction underscores the difference between evidence-based medicine and wellness supplements.

Incumbent animal health companies

Large pharmaceutical companies, including Zoetis, Elanco, and Boehringer Ingelheim, dominate veterinary medicine through established distribution networks and relationships. These incumbents primarily focus on disease treatment rather than prevention, leaving an opportunity for Loyal's aging-focused approach.

Incumbents benefit from significant advantages in manufacturing scale, regulatory expertise, and veterinary relationships, which could enable faster competitive responses if the longevity market demonstrates viability. However, their current business models prioritize treating sick animals over addressing aging in healthy pets.

TAM Expansion

New products

Beyond the initial three longevity drugs, Loyal's clinical trial biobank of 1,300 dogs provides a foundation for companion diagnostics and aging biomarker panels. The company could develop veterinary testing services to identify dogs most likely to benefit from longevity interventions, similar to Zoetis' approach of integrating diagnostics businesses with drug sales.

Research into aging also highlights additional therapeutic targets, including cognitive decline, joint health, and immune system support. Each new indication increases the addressable population and creates opportunities for combination therapies targeting multiple aspects of canine aging.

Customer base expansion

The conditional approval pathway allows for immediate market entry through veterinary channels while generating evidence to support broader adoption. Corporate veterinary groups such as Mars Veterinary Health and Chewy's clinic network are actively exploring senior care offerings, providing distribution scale to facilitate market entry.

Direct-to-consumer opportunities are available through online pharmacy channels and subscription services, particularly as pet insurance coverage expands to include preventive longevity treatments. The pet insurance market in North America, which includes over 6 million policies, could help reduce cost barriers for pet owners.

Geographic expansion

International markets offer growth potential following FDA approval, which could establish a regulatory precedent. The European Union's veterinary medicine regulations permit streamlined approval processes based on FDA data packages, enabling faster entry into markets with over 100 million pet dogs.

Asia-Pacific markets, particularly China with its 110 million pet dogs, present long-term opportunities as pet humanization trends increase spending on advanced veterinary care. Local partnerships could address regulatory requirements and build distribution networks in these high-growth regions.

Risks

Efficacy validation: Loyal's conditional approval pathway requires demonstrating full drug efficacy within five years of launch through ongoing clinical studies. If longevity benefits do not materialize in real-world use, the FDA may revoke approval, undermining the business model before competitors undergo equivalent scrutiny.

Manufacturing scale-up: Transitioning from clinical trial production to commercial manufacturing introduces operational risks, particularly for a company constructing its own facilities instead of relying on established contract manufacturers. Quality control failures or supply chain disruptions during launch could harm veterinary relationships and delay adoption.

Human longevity expectations: The company's long-term strategy relies on extending canine longevity success to human applications, a shift that entails significantly higher development costs and regulatory barriers. If the human longevity market does not develop as projected, Loyal will remain limited to the smaller veterinary pharmaceutical sector.

DISCLAIMERS

This report is for information purposes only and is not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to your individual circumstances or otherwise constitutes a personal trade recommendation to you.

This research report has been prepared solely by Sacra and should not be considered a product of any person or entity that makes such report available, if any.

Information and opinions presented in the sections of the report were obtained or derived from sources Sacra believes are reliable, but Sacra makes no representation as to their accuracy or completeness. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a determination at its original date of publication by Sacra and are subject to change without notice.

Sacra accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that liability arises under specific statutes or regulations applicable to Sacra. Sacra may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect different assumptions, views and analytical methods of the analysts who prepared them and Sacra is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

All rights reserved. All material presented in this report, unless specifically indicated otherwise is under copyright to Sacra. Sacra reserves any and all intellectual property rights in the report. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of Sacra. Any modification, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, or selling any report is strictly prohibited. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Sacra. Any unauthorized duplication, redistribution or disclosure of this report will result in prosecution.

Published on Aug 25th, 2025